|
|
|
|
|
Tolbutamide
drug data and news
Tolbutamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Tolbutamide | ||
| Brand Names/Synonyms | Aglicid; Apo-Tolbutamide; Arkozal; Artosin; Artozin; BZ 55; Butamid; Butamide; D 860; Diaben; Diabetamid; Diabetol; Diabuton; Diasulfon; Dirastan; Dolipol; Drabet; Glyconon; HLS 831; Ipoglicone; Mobenol; Novo-Butamide; Orabet; Oralin; Orezan; Orinase; Orinase Diagnostic; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Sk-Tolbutamide; Tolbusal; Tolbutamid; Tolbutamide; Tolbutamide.; Toluina; Tolumid; Toluvan; Tolylsulfonylbutylurea; U-2043; Willbutamide | ||
| Indication | For the management of hyperglycemia in non-insulin-dependent diabetes mellitus (NIDDM) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Tolbutamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Tolbutamide is twice as potent as the related second-generation agent glipizide. | ||
| Mechanism Of Action | Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. | ||
| Tolbutamide News (When available) |
Cell specificity of the cytoplasmic Ca 2+ response to tolbutamide ... May 10, 2006 Shin Nippon Biomedical Laboratories Obtains New Knowledge on Drug ... May 8, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Hypoglycemic Agents; Sulfonylureas; ATC:A10BB03; ATC:V04CA01 | ||
| Absorption | Well absorbed, not affected by food consumption | ||
| Interactions | Not Available | ||
| Toxicity | Overodoses lead to hypoglycemia. LD50=2600 mg/kg (mice) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-butyl-1-(4-methylphenyl)sulfonyl-urea | ||
| Chemical Formula | C12H18N2O3S | ||
| Molecular Weight | 270.349 g/mol | ||
| Smiles String | CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C | ||
| Melting Point | 128.5 °C | ||
| Water Solubility | 109 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 2.765 | ||
| Isoelectric Point | 5.16 | ||
| Biotransformation | Primarily hepatic | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 60%-plasma | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Tolbutamide.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00267 | ||
| CAS Registry Number | 64-77-7 | ||
| KEGG Compound ID | C07148 | ||
| PubChem ID | SID:149066 | ||
| PharmGKB ID | PA451718 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 156663 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |